General Toxicity Notes
Blood levels most often the best guide to therapy. Half-life may be prolonged in heart failure or with reduced hepatic blood flow.
Excreted Unchanged %
35-65
Half-Life (Normalesrd) Hours
5-8/10-18
Plasma Protein Binding %
54-81
Volume Of Distribution L/Kg
0.8-2.6
Dose For Normal Renal Function
100-200 mg q6h
Adjustment For Renal Failure Method
I
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
q8h[A]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
q12-24h [A]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
q24-48h [A]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None
Supplement For Dialysis [Recommendation Level]: Pd
PD: None
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Dose for GFR 10-50, [D]
References
Brogden RN, Todd PA. Disopyramide. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias. Drugs. 1987; 34: 151-87. [PMID: 3304965] / Siddoway LA, Woosley RL. Clinical pharmacokinetics of disopyramide. Clin Phar-macokinet. 1986; 11: 214-22. [PMID: 3524956]
Toxicity Notes
Urinary retention. Vd decreased in ESRD.